There are 2934 resources available
Making fatigue visible: Results of the Lymphoma Coalition 2018 survey
Presenter: Guy Bouguet
Session: How can we better support cancer patients suffering from fatigue?
Resources:
Slides
Webcast
Tackling the many factors that contribute to fatigue
Presenter: Matti Aapro
Session: How can we better support cancer patients suffering from fatigue?
Resources:
Slides
Webcast
Is more research needed to support the integration of exercise into the standard health basket for cancer care?
Presenter: Joachim Wiskemann
Session: How can we better support cancer patients suffering from fatigue?
Resources:
Slides
Webcast
Molecular profiling, prognosis and present Guidelines for Relapsed/Refractory AML
Presenter: Lars Bullinger
Session: ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)
Resources:
Slides
Webcast
Recent results with FLT3 Inhibitors in FLT3-ITD positive Relapsed/Refractory AML and future development
Presenter: Jorge Cortes
Session: ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)
Resources:
Slides
Webcast
Introduction
Presenter: Bernard Escudier
Session: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
Resources:
Slides
Webcast
Present standard of care according to the 2019 ESMO Guidelines
Presenter: Manuela Schmidinger
Session: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
Resources:
Slides
Webcast
Comparative outcome in 1st line according to prognostic group and criteria for decision making
Presenter: Camillo Guglielmo Porta
Session: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
Resources:
Slides
Webcast
Options and criteria for treatment choice in 2nd and 3rd lines
Presenter: Ronald de Wit
Session: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
Resources:
Slides
Webcast
How to the sequence the use of drugs in a multi-lines’ strategy for RCC?
Presenter: Bernard Escudier
Session: ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
Resources:
Slides
Webcast